Hybrid polymeric systems of mesoporous silica/hydroxyapatite nanoparticles applied as antitumor drug delivery platform
Source abstract
Abstract
Abstract In this study, we report the production of a mesoporous silica/hydroxyapatite‐based nanocomposite containing copper (Cu) functionalized with methacrylic acid (MAA), a pH‐sensitive polymer. The functionalization of the nanoparticles surface was performed using the microwave method in order to anchor the cross‐linking tetraethylene glycol dimethacrylate (TEGDMA), onto the nanoparticles surface followed by MAA polymerization. The materials were characterized by XRD, XRF spectroscopy, scanning and transmission electron microscopy, Fourier transform infrared spectroscopy, thermal analysis, zeta potential, and elemental analysis. Studies of the incorporation and release of the antitumor methotrexate drug were performed in order to evaluate the potential use of these drug carrier systems in cancer therapy. Moreover, the in vitro cytotoxicity of the samples in fibroblast and SAOS‐2 cells was investigated, and the activity of the adipose‐derived stem cell alkaline phosphatase on nanocomposites was studied by in vitro assays. The results indicate that the Cu‐containing nanocomposites can be easily produced and that these compositions have beneficial effects in stem cells, maintaining cell viability, and allowing alkaline phosphatase expression. In conclusion, data from this work show that the nanocomposites obtained have adequate characteristic to be used as drug delivery platform. Furthermore, the biomaterial is a promising structure for treatment of bone tumor.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Nanoparticle-Based Drug Delivery · biodegradable polymer synthesis and properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center of Development of the Nuclear Technology, CDTN/CNEN Belo Horizonte Brazil
Departament of Biochemistry and Immunology, Institute of Biological Science Federal University of Minas Gerais (UFMG) Belo Horizonte Brazil
Funding
Fundação de Amparo à Pesquisa do Estado de Minas Gerais · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
References (53)
Show source-provided references
1. Utility of nanomedicine for cancer treatment
2. 10.1016/j.addr.2012.09.00610.1016/j.addr.2012.09.006 ↗
3. Functionalized hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image‐guided
4. 10.1021/acsami.7b1928110.1021/acsami.7b19281 ↗
5. 10.1038/nrd433310.1038/nrd4333 ↗
6. 10.1246/bcsj.63.98810.1246/bcsj.63.988 ↗
7. 10.1016/j.addr.2012.07.01810.1016/j.addr.2012.07.018 ↗
8. 10.1021/cm96013810.1021/cm960138 ↗
9. 10.1021/ja00053a02010.1021/ja00053a020 ↗
10. 10.1016/j.jeurceramsoc.2007.12.00110.1016/j.jeurceramsoc.2007.12.001 ↗
11. 10.1097/00003086-200202000-0000910.1097/00003086-200202000-00009 ↗
12. 10.1016/j.actbio.2005.12.00610.1016/j.actbio.2005.12.006 ↗
13. Study of hydroxyapatite osteoinductivity with an osteogenic differentiation of mesenchymal stem cells
14. 10.1016/j.msec.2016.10.06610.1016/j.msec.2016.10.066 ↗
15. 10.1016/j.msec.2016.02.06210.1016/j.msec.2016.02.062 ↗
16. 10.1166/jbn.2013.148210.1166/jbn.2013.1482 ↗
17. 10.1007/s10856-014-5273-610.1007/s10856-014-5273-6 ↗
18. 10.1039/C6PY01585A10.1039/C6PY01585A ↗
19. 10.1016/j.biotechadv.2013.11.00910.1016/j.biotechadv.2013.11.009 ↗
20. 10.1039/c2tb00223j10.1039/c2tb00223j ↗
21. 10.1016/j.colsurfb.2016.11.01610.1016/j.colsurfb.2016.11.016 ↗
22. 10.1016/j.actbio.2017.04.01210.1016/j.actbio.2017.04.012 ↗
23. 10.1016/j.actbio.2015.11.03310.1016/j.actbio.2015.11.033 ↗
24. Adequate serum copper concentration could improve bone density, postpone bone loss and protect osteoporosis in women
25. 10.1016/j.biomaterials.2012.09.06610.1016/j.biomaterials.2012.09.066 ↗
26. 10.1016/j.ejps.2011.10.01610.1016/j.ejps.2011.10.016 ↗
27. 10.1200/JCO.2007.14.779310.1200/JCO.2007.14.7793 ↗
28. Mechanisms of methotrexate resistance in osteosarcoma
29. 10.1080/10717544.2016.120979610.1080/10717544.2016.1209796 ↗
30. 10.3109/10717544.2013.83871410.3109/10717544.2013.838714 ↗
31. 10.1007/s10971-017-4557-y10.1007/s10971-017-4557-y ↗
32. 10.1016/j.micromeso.2017.01.03610.1016/j.micromeso.2017.01.036 ↗
33. 10.1007/s12015-014-9529-910.1007/s12015-014-9529-9 ↗
34. 10.1021/cm303719710.1021/cm3037197 ↗
35. 10.1039/C6BM00039H10.1039/C6BM00039H ↗
36. 10.1016/j.ceramint.2018.06.24810.1016/j.ceramint.2018.06.248 ↗
37. 10.1007/s10856-014-5273-610.1007/s10856-014-5273-6 ↗
38. 10.1016/j.nanoso.2017.09.01410.1016/j.nanoso.2017.09.014 ↗
39. 10.4028/www.scientific.net/KEM.493-494.62610.4028/www.scientific.net/KEM.493-494.626 ↗
40. 10.1039/C5RA07330H10.1039/C5RA07330H ↗
41. 10.1016/j.carbon.2010.12.04510.1016/j.carbon.2010.12.045 ↗
42. 10.1016/j.actbio.2007.11.00310.1016/j.actbio.2007.11.003 ↗
43. 10.1016/j.surfrep.2014.07.00110.1016/j.surfrep.2014.07.001 ↗
44. 10.1016/j.eurpolymj.2010.11.00710.1016/j.eurpolymj.2010.11.007 ↗
45. Supplementary information tailored silica nanoparticles surface to increase drug load and enhance
46. 10.1016/j.jconrel.2006.11.01710.1016/j.jconrel.2006.11.017 ↗
47. 10.1016/0142-9612(95)91130-Q10.1016/0142-9612(95)91130-Q ↗
48. 10.1016/S0168-3659(02)00019-610.1016/S0168-3659(02)00019-6 ↗
49. 10.1016/j.jconrel.2003.12.02210.1016/j.jconrel.2003.12.022 ↗
50. 10.1016/j.toxrep.2014.05.00510.1016/j.toxrep.2014.05.005 ↗
51. 10.1016/j.scr.2013.12.00110.1016/j.scr.2013.12.001 ↗
52. 10.1084/jem.93.5.41510.1084/jem.93.5.415 ↗
53. Effects of two methacrylic monomers on pulp cells differentiation capability: a preliminary in vitro study